Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
Blood (2016)
  • Ruben Niesvizky, Cornell University
  • Paul G. Richardson, Harvard University
  • Andrew J. Yee, Harvard University
  • Ajay K Nooka, Emory University
  • Marc S Raab, Heidelberg University
  • Kenneth H. Shain, University of South Florida
  • Nashat Y. Gabrail, University of Washington
  • Jeffrey Matous, Cancer Institute
  • Amit B. Agarwal, University of Arizona
  • James Hoffman, University of Miami
  • Sumit Madan, University of Texas Health Science Center at San Antonio
  • John M. Pagel, Cancer Institute
  • Jesus San Miguel, Chartered Institute of Management Accountants
  • Philippe Moreau, University of Nantes
  • Maria-Victoria Mateos, University of Salamanca
  • Thierry Facon, Harvard University
  • David Tamang
  • Simon S Jones, Genetics Institute, Inc.
  • Robert J Markelewicz
  • Catherine Wheeler, Business International Corporation
  • Nikolaus S. Trede, Huntsman Cancer Institute
  • Noopur Raje, Harvard University
  • Evangelos Terpos, National and Kapodistrian University of Athens
  • William I. Bensinger, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
December 2, 2016
Citation Information
Ruben Niesvizky, Paul G. Richardson, Andrew J. Yee, Ajay K Nooka, et al.. "Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)" Blood Vol. 128 Iss. 22 (2016) p. 3307 - 3307
Available at: http://works.bepress.com/john-pagel/39/